Top-Rallying Biotech Stocks – Santarus, Inc. (NASDAQ:SNTS), InterMuneInc (NASDAQ:ITMN), Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Houston, TX – April 15, 2013 — (Net PR News) – AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Today’s Stocks in focus are: Santarus, Inc. (NASDAQ:SNTS), InterMuneInc (NASDAQ:ITMN), Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Santarus, Inc. (NASDAQ:SNTS) rose after holding an Investor and Analyst Day on April 11, 2013 at 9:00 AM ET in the Millennium Broadway Hotel, 145 West 44th Street, New York City.
Santarus, Inc. (NASDAQ:SNTS) moved up +4.64% and closed at $18.27 with the total traded volume of 1.48 million shares. Its opening price was $17.38.
This company has earnings per share of $0.26 with the net profit margin of 8.51% and operating margin of 9.26%. The company now has market cap of about $1.17 billion.
What was the Moving Force behind SNTS’ Bullish Run? Read This Research Report on SNTS
InterMuneInc (NASDAQ:ITMN) gained sharply as a number of the popular companies in biotechnology industry spiked to all-time highs Friday as Street analysts were issuing increasingly warm views of their shares.
InterMuneInc (NASDAQ:ITMN) gained +4.46% with the closing price of $9.61. The overall volume in the last trading session was 2.28 million shares. Its fifty two week range was $7.21-$12.77. The total market capitalization remained $784.18 million.
The stock is ahead of its 52 week low 33.29% and its last month price volatility remained 4.10%. Its beta coefficient was 2.27 with a target price of $14.64. In its share capital, the company has 81.60 million outstanding shares, while 65.36 million shares have been floated in the market.
For How Long will ITMN Fight for Profitability? Read This Trend Analysis report
It has insider ownership of 0.28%, with institutional ownership at 91.57%. Earnings per share this year dropped -4.89%
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rose to new high after Ladenburg Thalman analyst, Adolfo Rueda, rated the stock outperform and put a new, higher price target.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) advanced +3.59% and closed at $215.84 in the last trading session with the overall traded volume of 1.16 million shares, more versus the average volume of 638,854 shares. Its 52 weeks high price was $216.20 and it suffered its lowest price of $107.31 in the same period.
REGN has current ratio of 7.37 and its total debt-to-equity ratio is 0.37. It has market cap of $21.03 billion, while its total outstanding shares are 97.45 million. The stock’s beta value stands at 1.00 times.
For How Long will REGN’s Gloss Attract Investors? Find out via this report
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.